CN116158988A - Skin care composition with whitening and anti-aging effects and application thereof - Google Patents
Skin care composition with whitening and anti-aging effects and application thereof Download PDFInfo
- Publication number
- CN116158988A CN116158988A CN202310277767.8A CN202310277767A CN116158988A CN 116158988 A CN116158988 A CN 116158988A CN 202310277767 A CN202310277767 A CN 202310277767A CN 116158988 A CN116158988 A CN 116158988A
- Authority
- CN
- China
- Prior art keywords
- whitening
- skin
- skin care
- aging effects
- care composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 230000002087 whitening effect Effects 0.000 title claims abstract description 25
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 36
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 27
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 21
- 229960003180 glutathione Drugs 0.000 claims abstract description 19
- 108010024636 Glutathione Proteins 0.000 claims abstract description 18
- 102000003425 Tyrosinase Human genes 0.000 claims abstract description 14
- 108060008724 Tyrosinase Proteins 0.000 claims abstract description 14
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 6
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 6
- 239000011570 nicotinamide Substances 0.000 claims abstract description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 15
- 229920002674 hyaluronan Polymers 0.000 claims description 15
- 229960003160 hyaluronic acid Drugs 0.000 claims description 15
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 6
- 230000003020 moisturizing effect Effects 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229940035423 ethyl ether Drugs 0.000 abstract description 16
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 231100000344 non-irritating Toxicity 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 61
- 230000000052 comparative effect Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 17
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 3
- 102000016387 Pancreatic elastase Human genes 0.000 description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 3
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 3
- 206010040914 Skin reaction Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- -1 lipid peroxide Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000001782 photodegradation Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000035483 skin reaction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 101000713272 Homo sapiens Solute carrier family 22 member 4 Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102100036928 Solute carrier family 22 member 4 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000009013 pigment accumulation Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a skin care composition with whitening and anti-aging effects, which is characterized by comprising the following functional components: ergothioneine, VC ethyl ether, glutathione. The invention discovers for the first time that ergothioneine, VC ethyl ether, nicotinamide and glutathione have remarkable synergistic effect in inhibiting tyrosinase activity. Through scientific compatibility, the whitening and anti-aging effects of the product are realized through multiple paths, meanwhile, the product is safe and non-irritating, is suitable for sensitive muscles, can synergistically inhibit tyrosinase activity and remove free radicals, and can effectively achieve the whitening and anti-aging effects.
Description
Technical Field
The invention belongs to the field of skin care products, and particularly relates to a skin care composition with whitening and anti-aging effects and application thereof.
Background
Skin is the largest organ of the human body, and particularly the skin exposed to the outside contains a large amount of sebum with the age, is constantly contacted with oxygen and is often affected by ultraviolet irradiation and the like, so that the skin is the organ most susceptible to chemical reactions including active oxygen, lipid peroxide and the like, free radicals can react with biological molecules of the skin to cause lipid peroxidation damage, damage and aging of the skin are caused, and the skin becomes rough, wrinkled and blackened gradually, and senile plaques grow. Sunlight irradiation and human mitochondria respiratory chain generate excessive free radicals, the free radicals act on an enzyme system in a human body, so that collagenase and elastase are released, the collagenase and elastase act on collagen and elastin in skin and cause excessive crosslinking and degradation of the two proteins, and as a result, the skin loses elasticity, looses and weakness, wrinkles and vesicles even occur, and epidermal melanocyte proliferation and activation are carried out, dopamine reaction is enhanced, and pigment excessive deposition at an illumination part is caused.
Disclosure of Invention
The invention aims to: aiming at the defects of the prior art, the technical problem to be solved by the invention is to provide the skin care composition which is safe, has no stimulation, is suitable for sensitive muscles and has the effects of whitening and resisting aging, and the application thereof.
In order to achieve the above object, the present invention adopts the following technical scheme;
a skin care composition with whitening and anti-aging effects comprises the following functional components: ergothioneine, VC ethyl ether, glutathione.
The ergothioneine is a natural antioxidant, and the stability of the ergothioneine is obviously superior to that of common antioxidants due to the special physicochemical properties and specific distribution, and the oxidation resistance of the ergothioneine can be compared with that of conventionally recognized antioxidants such as Glutathione (GSH), ascorbic acid and the like. The free radicals act on the enzyme system in the human body, resulting in the release of collagenase and elastase, which act on collagen and elastin in the skin and cause excessive crosslinking and degradation of these 2 proteins, with the result that the skin loses elasticity, relaxes and is weak, and wrinkles appear in the human body, resulting in aging. Ergothioneine enters cells in vivo through OCTN1, reduces ROS generated by ultraviolet oxidative stress in the cells, prevents protein, DNA and lipid from being damaged, and achieves the anti-aging effect. Studies have shown that ergothioneine can inhibit the expression of tumor necrosis factor-alpha (TNF-alpha) and MMP-1, reducing ROS levels, while ROS, TNF-alpha and MMP-1 play an important role in UV-induced skin aging, particularly wrinkle formation. Meanwhile, the ergothioneine can inhibit tyrosinase activity, prevent pigmentation, lighten skin color and whiten skin.
However, ergothioneine is susceptible to degradation by light, with higher concentrations leading to faster degradation rates. The invention discovers for the first time that the combination of glutathione and VC ethyl ether can inhibit the photodegradation of ergothioneine.
The VC ethyl ether can directly participate in collagen synthesis after entering the dermis layer, repair the activity of skin cells, and increase the collagen, so that the skin becomes full and elastic, the skin is fine and smooth, the tyrosinase activity is inhibited, the formation of melanin is inhibited, and the melanin is reduced to be colorless, thereby achieving the effect of whitening the skin.
Glutathione is a small molecular active oligopeptide, and the antioxidation effect of the glutathione depends on a GSH-peroxidase-reductase (GSH-Px-Rx) system, and can remove harmful free radicals and lipid peroxides in the body, so that skin aging and pigment accumulation are prevented, skin is glossy, and the glutathione is often used as a skin conditioner.
Further, the skin care composition of the present invention further comprises niacinamide, the whitening mechanism of which comprises three of the following: (1) inhibiting melanin granule formation; (2) inhibiting melanin transfer to keratinocytes; (3) Accelerating the transfer of melanin from glial cells to the stratum corneum and promoting exfoliation of the stratum corneum. The invention discovers for the first time that ergothioneine, VC ethyl ether, nicotinamide and glutathione have remarkable synergistic effect in inhibiting tyrosinase activity.
Still further, the skin care composition of the present invention further comprises hyaluronic acid or a salt thereof.
Sodium hyaluronate is an inherent component of skin, and the content of sodium hyaluronate in epidermis and dermis of human body is more than half. The sodium hyaluronate with different molecular weights has different action effects: the macromolecular sodium hyaluronate acts on the surface of skin to form a layer of film, which plays roles in lubricating the skin, blocking bacteria and ultraviolet injury, and simultaneously prevents the evaporation of moisture in the skin so as to achieve the aim of moisturizing; the medium molecular sodium hyaluronate can reach the skin cuticle, so that the moisturizing effect is good; the small molecule hydrolyzed sodium hyaluronate can be partially absorbed through skin to reach dermis layer, enter into skin for deep moisture preservation, and promote repair.
Specifically, the hyaluronic acid or the salt thereof is at least one selected from hyaluronic acid, hydrolyzed hyaluronic acid, sodium hyaluronate, hydrolyzed sodium hyaluronate, sodium hyaluronate crosslinked polymer and acetylated sodium hyaluronate.
Still further, the skin care composition of the present invention comprises 0.01 to 5wt% ergothioneine, 0.1 to 3.0wt% VC ethyl ether, 0.1 to 3wt% nicotinamide, 0.001 to 3wt% glutathione, 0.01 to 5wt% hyaluronic acid or a salt thereof, and the balance water.
Furthermore, the skin care composition can be prepared into any dosage form of cream, emulsion, essence, moisturizing water and mask liquid independently or together with common auxiliary materials.
Still further, the present invention claims the use of the above composition for whitening skin.
Still further, the present invention claims the use of the above composition for anti-aging of skin.
Furthermore, the use of the above composition for inhibiting tyrosinase activity is claimed.
The beneficial effects are that:
(1) The VC ethyl ether and nicotinamide have whitening effect only at high concentration, and the high concentration of VC ethyl ether and nicotinamide has high irritation and can cause skin allergy. The skin care composition comprises ergothioneine, VC ethyl ether, nicotinamide, glutathione, hyaluronic acid or salts thereof, achieves the effects of whitening and resisting aging of the product through scientific compatibility and multiple paths, meets the requirements of safety and no stimulation of the product, and is suitable for sensitive muscles.
(2) The raw materials of the skin care composition disclosed by the invention can synergistically inhibit the activity of tyrosinase and remove free radicals, and can effectively achieve the effects of whitening and resisting aging.
(3) In the skin care composition, the VC ethyl ether and the glutathione have the effect of inhibiting the photodegradation of ergothioneine.
Detailed Description
The invention will be better understood from the following examples.
Example 1
A skin care product composition comprising, based on the total weight of the skin care product composition: 0.025wt% of ergothioneine, 1wt% of VC ethyl ether, 1wt% of nicotinamide, 0.02wt% of glutathione, 0.5wt% of hyaluronic acid or a salt thereof, and the balance of water.
Example 2
A skin care product composition comprising, based on the total weight of the skin care product composition: 0.05wt% of ergothioneine, 1wt% of VC ethyl ether, 0.5wt% of nicotinamide, 0.02wt% of glutathione, 0.5wt% of hyaluronic acid or a salt thereof, and the balance of water.
Example 3
A skin care product composition comprising, based on the total weight of the skin care product composition: 0.1wt% of ergothioneine, 0.8wt% of VC ethyl ether, 0.5wt% of nicotinamide, 0.01wt% of glutathione, 0.5wt% of hyaluronic acid or a salt thereof, and the balance of water.
The formulations of the examples and the comparative examples are shown in Table 1.
TABLE 1
Performance and efficacy testing
1. Evaluation of whitening efficacy
In skin melanin biosynthesis, tyrosinase is a key enzyme that acts on dopa to form dopaquinone, which spontaneously undergoes a series of reactions to ultimately form melanin. Thus, inhibition of tyrosinase activity may reflect the whitening efficacy of the test sample.
The testing method comprises the following steps: the test samples prepared in examples 1 to 3 and comparative examples 1 to 10 were examined for tyrosinase activity inhibition according to T/SHRH 015 "cosmetic-tyrosinase activity inhibition test method", and the results are shown in Table 2.
TABLE 2
| Test sample | Tyrosinase inhibition rate (%) |
| Example 1 | 99 |
| Example 2 | 100 |
| Example 3 | 100 |
| Comparative example 1 | 50.5 |
| Comparative example 2 | 38.2 |
| Comparative example 3 | 16.7 |
| Comparative example 4 | 38.2 |
| Comparative example 5 | 23.6 |
| Comparative example 6 | 15.3 |
| Comparative example 7 | 36.7 |
| Comparative example 8 | 53.2 |
| Comparative example 9 | 69.7 |
| Comparative example 10 | 32.1 |
| Comparative example 11 | 47.8 |
| Comparative example 12 | 66.5 |
From the results in table 2, it can be seen that:
(1) The cosmetic compositions prepared in examples 1-3 have a good tyrosinase activity inhibition rate of up to 99% -100%, which is superior to that of the control.
(2) The components of the skin care product composition have a synergistic effect on inhibiting tyrosinase activity.
2. Evaluation of anti-aging efficacy
Skin is a barrier that protects tissue organs in the body from mechanical, physical, chemical and biological attack. With age, the protective function of the skin can change over a range of times. The irreparable damage to skin cells caused by free radicals is one of the causes of premature skin aging. The antioxidant can prevent free radical from damaging skin, and the antioxidant generated by human body is insufficient to prevent free radical from damaging skin, and skin care raw material with free radical scavenging capability can effectively delay skin aging. The application evaluates the anti-aging efficacy of skin care compositions by measuring their total antioxidant capacity (scavenging ABTS free radicals).
The testing method comprises the following steps: the test samples prepared in examples 1-3 and comparative examples 1-10 were tested for radical scavenging ability (after dilution to 0.3% sample solutions, respectively) according to GB/T39100 "ABTS+radical scavenging method", and the results are shown in Table 3.
TABLE 3 Table 3
| Test sample | ABTS radical clearance (%) |
| Example 1 | 98.9 |
| Example 2 | 99.7 |
| Example 3 | 96.5 |
| Comparative example 1 | 80.7 |
| Comparative example 2 | 74.2 |
| Comparative example 3 | 59.7 |
| Comparative example 4 | 18.5 |
| Comparative example 5 | 13.3 |
| Comparative example 6 | 8.8 |
| Comparative example 7 | 63.7 |
| Comparative example 8 | 66.1 |
| Comparative example 9 | 70.1 |
| Comparative example 10 | 6.5 |
| Comparative example 11 | 12.4 |
| Comparative example 12 | 24.3 |
The results in Table 3 show that:
the skin care product composition disclosed in the application has higher free radical removal rate in examples 1-3, and each component has obvious synergistic effect in free radical removal, so that the skin care product composition disclosed in the application has better anti-aging effect.
3. Safety evaluation-human skin patch test
Testing the product: the skin care product compositions of examples 1 to 3 of the present invention were prepared by adding preservative (0.5% of p-hydroxyacetophenone and 0.5% of 1, 2-hexanediol) as test substances, respectively, and pure water as a control.
The subject: 35 persons, meeting the volunteer selection standard of the subjects.
The testing method comprises the following steps: selecting proper patch equipment, placing about 0.02-0.025 ml of the test objects into the patch equipment (the patch equipment is 10 holes, each test object is added with 2 holes), attaching the patch equipment to the bending side of the forearm of a subject, uniformly applying the patch equipment to the skin by using palm light pressure, removing the test objects after 24 hours, observing skin reactions after 0.5 hour, 24 hours and 48 hours respectively, and recording results according to the skin reaction powder standard in cosmetic safety technical Specification (2015).
The results of the human patch test are shown in Table 4.
TABLE 4 Table 4
Remarks: 0 is negative reaction, which means no adverse reaction of skin, 1-4 is adverse reaction of different degrees of skin, and specific clinical manifestations of skin reaction are seen in cosmetic safety technical Specification (2015 edition).
The results in combination with Table 4 show that: the skin care product compositions prepared in examples 1-3 were safe and non-irritating without any skin adverse reactions.
4. Ergothioneine photodegradation test
Solutions were prepared as shown in the following table and the initial ergothioneine content in the solutions was measured. The solutions were respectively packaged into 10 ml/bottle, placed under outdoor sunlight, left for 15 days, sampled, and the content of ergothioneine in the solutions was respectively detected, and the retention rate of ergothioneine was calculated, and the results are shown in Table 5.
TABLE 5
The results in Table 5 show that: the degradation rate of the ergothioneine is inhibited by adding VC ethyl ether into the ergothioneine solution, and the degradation rate of the ergothioneine is further reduced by adding VC ethyl ether and glutathione.
The invention provides a skin care composition with whitening and anti-aging effects, and an application idea and a method thereof, and the method and the way for realizing the technical scheme are numerous, the above description is only a preferred embodiment of the invention, and it should be pointed out that a plurality of improvements and modifications can be made to those skilled in the art without departing from the principle of the invention, and the improvements and modifications are also considered as the protection scope of the invention. The components not explicitly described in this embodiment can be implemented by using the prior art.
Claims (10)
1. A skin care composition with whitening and anti-aging effects is characterized by comprising the following functional components: ergothioneine, VC ethyl ether, glutathione.
2. The skin care composition having whitening and anti-aging effects according to claim 1, further comprising niacinamide.
3. The skin care composition having whitening and anti-aging effects according to claim 1, further comprising hyaluronic acid or a salt thereof.
4. The skin care composition having whitening and anti-aging effects according to claim 2, further comprising hyaluronic acid or a salt thereof.
5. The skin care composition having whitening and anti-aging effects according to claim 3 or 4, wherein the hyaluronic acid or the salt thereof is at least one selected from the group consisting of hyaluronic acid, hydrolyzed hyaluronic acid, sodium hyaluronate, hydrolyzed sodium hyaluronate, sodium hyaluronate crosslinked polymer, and acetylated sodium hyaluronate.
6. The skin care composition having whitening and anti-aging effects according to claim 4, which comprises 0.01 to 5wt% of ergothioneine, 0.1 to 3.0wt% of VC ethyl ether, 0.1 to 3wt% of nicotinamide, 0.001 to 3wt% of glutathione, 0.01 to 5wt% of hyaluronic acid or a salt thereof, and the balance water.
7. The skin care composition with whitening and anti-aging effects according to any one of claims 1 to 4 and 6, which can be prepared into any dosage form of cream, emulsion, essence, moisturizing water and mask liquid alone or together with common auxiliary materials.
8. Use of a composition according to any one of claims 1 to 4 for whitening skin.
9. Use of a composition according to any one of claims 1 to 4 for anti-aging of skin.
10. Use of a composition according to any one of claims 2 to 4 for inhibiting tyrosinase activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310277767.8A CN116158988B (en) | 2023-03-21 | 2023-03-21 | Skin care composition with whitening and anti-aging effects and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310277767.8A CN116158988B (en) | 2023-03-21 | 2023-03-21 | Skin care composition with whitening and anti-aging effects and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116158988A true CN116158988A (en) | 2023-05-26 |
| CN116158988B CN116158988B (en) | 2024-09-13 |
Family
ID=86411533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310277767.8A Active CN116158988B (en) | 2023-03-21 | 2023-03-21 | Skin care composition with whitening and anti-aging effects and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116158988B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124409A1 (en) * | 2000-11-21 | 2008-05-29 | Access Business Group International Llc | Topical Skin Compositions, Their Preparation, and Their Use |
| JP2009126863A (en) * | 2007-11-27 | 2009-06-11 | Koei Kogyo Kk | Composition highly containing ergothioneine extracted from mushroom |
| US20140271510A1 (en) * | 2011-11-30 | 2014-09-18 | Ajinomoto Co., Inc. | Whitening cosmetic |
| CN110327242A (en) * | 2019-07-29 | 2019-10-15 | 华熙生物科技股份有限公司 | Method for inhibiting ergothioneine photodegradation and application thereof |
| CN114306118A (en) * | 2021-12-08 | 2022-04-12 | 精晶药业股份有限公司 | Whitening anti-aging skin care composition and application thereof |
| CN114681358A (en) * | 2022-02-16 | 2022-07-01 | 合肥卡迪尔生物科技有限公司 | Tyrosinase activity inhibitor and skin care product with synergistic whitening effect |
| CN114712258A (en) * | 2022-04-29 | 2022-07-08 | 广州市百好博有限公司 | Cosmetic composition with full-effect whitening, anti-aging and repairing effects |
| CN114732754A (en) * | 2022-05-06 | 2022-07-12 | 宁波伯通伟达生物医药有限公司 | Composition with skin whole-link antioxidation and anti-aging functions and preparation method and application thereof |
| CN115040429A (en) * | 2022-07-18 | 2022-09-13 | 华熙生物科技股份有限公司 | Anti-aging composition and application thereof |
-
2023
- 2023-03-21 CN CN202310277767.8A patent/CN116158988B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080124409A1 (en) * | 2000-11-21 | 2008-05-29 | Access Business Group International Llc | Topical Skin Compositions, Their Preparation, and Their Use |
| JP2009126863A (en) * | 2007-11-27 | 2009-06-11 | Koei Kogyo Kk | Composition highly containing ergothioneine extracted from mushroom |
| US20140271510A1 (en) * | 2011-11-30 | 2014-09-18 | Ajinomoto Co., Inc. | Whitening cosmetic |
| CN110327242A (en) * | 2019-07-29 | 2019-10-15 | 华熙生物科技股份有限公司 | Method for inhibiting ergothioneine photodegradation and application thereof |
| CN114306118A (en) * | 2021-12-08 | 2022-04-12 | 精晶药业股份有限公司 | Whitening anti-aging skin care composition and application thereof |
| CN114681358A (en) * | 2022-02-16 | 2022-07-01 | 合肥卡迪尔生物科技有限公司 | Tyrosinase activity inhibitor and skin care product with synergistic whitening effect |
| CN114712258A (en) * | 2022-04-29 | 2022-07-08 | 广州市百好博有限公司 | Cosmetic composition with full-effect whitening, anti-aging and repairing effects |
| CN114732754A (en) * | 2022-05-06 | 2022-07-12 | 宁波伯通伟达生物医药有限公司 | Composition with skin whole-link antioxidation and anti-aging functions and preparation method and application thereof |
| CN115040429A (en) * | 2022-07-18 | 2022-09-13 | 华熙生物科技股份有限公司 | Anti-aging composition and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| F FRANZONI等: "An in vitro study on the free radical scavenging capacity of ergothioneine: comparison with reduced glutathione, uric acid and trolox", BIOMEDICINE & PHARMACOTHERAPY, vol. 60, no. 8, 30 September 2006 (2006-09-30), pages 453 - 457 * |
| 李轶群;周念波;: "麦角硫因的生物学功能及其应用", 食品工程, no. 03 * |
| 毛培坤: "美白化妆品的发展动向", 食品与生物技术学报, no. 02 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116158988B (en) | 2024-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111686029A (en) | Anti-aging wrinkle-removing composition | |
| US11213479B2 (en) | Cosmetic composition comprising a passionflower extract and edelweiss cells, and uses | |
| JP2006225286A (en) | Dpph(1,1-diphenyl-2-picrylhydrazyl) radical scavenger, sod(superoxide dismutase) activity-like agent, skin-brightening preparation, l-dopa(l-2,3-dihydroxyphenylalanine) autoxidation inhibitor, collagenase activity inhibitor | |
| CN108113920A (en) | A kind of sustained release compound moisturizing face cream matrix of whitening and its preparation method and application | |
| KR101915655B1 (en) | Cosmetic composition containing Croton Lechleri resin extract | |
| CN112716839B (en) | Composition for resisting oxidation and repairing oxidative damage and application thereof | |
| CN116158988B (en) | Skin care composition with whitening and anti-aging effects and application thereof | |
| KR20110013812A (en) | Cosmetic composition containing salicornia herbacea callus extracts and laminaria digitata extracts for improving skin wrinkle or enhancing skin elasticity | |
| CN108324667A (en) | Composition and anti-aging Skin whitening care cosmetics containing light black huge marine algae extract | |
| WO2014167557A1 (en) | Cosmetic topical skin treatment formulation | |
| KR20090130743A (en) | Cosmetic compositions for preventing skin aging or whitening skin comprising extracts from ficus erecta thunb | |
| CN115400067A (en) | Skin whitening composition | |
| KR101725969B1 (en) | A cosmetic composition effective for skin whitening comprising multiple herbal extracts | |
| Aricioglu et al. | Changes in zinc levels and superoxide dismutase activities in the skin of acute, ultraviolet-B-irradiated mice after treatment with ginkgo biloba extract | |
| KR20070102630A (en) | Manufacturing method and cosmetic compositions preventing skin aging | |
| CN108403524A (en) | A kind of efficient spot-eliminating composition and its application | |
| KR20090078082A (en) | The skin beautifing cosmetic composition containing vitamin c and the extract of opuntia ficus-indica l. var. saboten makino flowers | |
| KR102135551B1 (en) | A cosmetic composition comprising red propolis extract having formononetin as a maker compound with excellent anti aging effect | |
| KR100472919B1 (en) | Water soluble whitening composition and cosmetic composition for whitening skin comprising the same | |
| CN111000765A (en) | Whitening composition containing ginseng enzyme and application thereof | |
| KR100424728B1 (en) | Whitening and wrinkle improvement cosmetics composition containing Areca catechu extract and Arbutin | |
| Vo et al. | Cosmeceutical compounds from marine sources | |
| KR100574850B1 (en) | Skin care composition containing synthetic palmitoyl pentapeptide | |
| KR101461204B1 (en) | Composition for skin external application comprising phosphatidylcholine and plant extracts | |
| CN114748389B (en) | Essence liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |